Aktuellt
SENASTE
Redeye leaves a comment on Idogen following the report for the third quarter of 2021. The report did not contain any significant surprises, and Idogen’s focus is on preparing IDO 8 for the clinical trial expected to commence in Q2 2022.
LÄS MER
